Key result
Previous statin therapy before acute coronary syndrome was associated with a lower incidence of in-hospital major cardiovascular events, with lack of prior statin use being an independent predictor of major cardiovascular events.
Why the study?
Does previous statin therapy initiated ≥1 month before PCI reduce periprocedural MI and in-hospital MACE in patients with ACS?
Cohort (n=479)
No
Does previous statin therapy initiated ≥1 month before PCI reduce periprocedural MI and in-hospital MACE in patients with ACS?
Previous statin therapy initiated at least 1 month before PCI in ACS patients is associated with a significantly lower incidence of periprocedural MI and in-hospital MACE.
Answers are grounded in this paper and cite their sources.
Supports statin pretreatment association in ACS; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND AND OBJECTIVES: Statin therapy after percutaneous coronary intervention (PCI) has been associated with reduced major adverse cardiovascular events (MACE). However, it has been less clear as to whether statin therapy before acute coronary syndrome (ACS) is beneficial. We studied the effect of previous statin therapy, initiated ≥1 month before PCI, on the outcome of patients with ACS who had undergone early invasive strategies. SUBJECTS AND METHODS: We stratified 479 consecutive patients with ACS who had undergone PCI, according to preprocedural statin administration as follows: previous statin-treated patients (statin group, n=237) and statin-naive patients (control group, n=242). The incidence of periprocedural myocardial infarction (MI) and in-hospital MACE was assessed. RESULTS: The incidence of Braunwald class III angina and MI presentation were significantly lower in the statin group than in the control group. Angiographic and procedural characteristics were similar between the two groups; however, slow/no reflow phenomenon occurred more frequently in the control group. After PCI, the incidence of periprocedural MI was higher in the control group than in the statin group (6.6% vs. 2.1%, p=0.016). Multivariate analysis revealed that no prior use of statin {odds ratio (OR)=2.8; 95% confidence interval (CI)=1.1-7.2; p=0.038), procedural complication (OR=4.0; 95% CI=1.5-10.5; p=0.004), stent overlap (OR=4.7; 95% CI=1.3-16.4; p=0.015), and old age (OR=3.2; 95% CI=1.2-8.0; p=0.016) were independent predictors for in-hospital MACE. CONCLUSION: Previous statin therapy before ACS was associated with milder clinical presentation and lower incidence of in-hospital MACE after early invasive strategies. The beneficial outcome is attributable to a significant reduction in periprocedural MI after PCI.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2011) conducted a cohort in Acute Coronary Syndrome (ACS) undergoing Percutaneous Coronary Intervention (PCI) (n=479). Previous statin therapy (≥1 month before PCI) vs. Statin-naive was evaluated on In-hospital major adverse cardiovascular events (MACE) (OR 2.8, 95% CI 1.1-7.2, p=0.038). Previous statin therapy before acute coronary syndrome was associated with a lower incidence of in-hospital major cardiovascular events, with lack of prior statin use being an independent predictor of major cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: